摘要
背景:细胞色素P450(CYP)2C19代谢美芬妥英的酶活性在人群中呈快代谢型和慢代谢型二态分布。突变型等位基因是CYP2C19基因多态性的分子生物学基础。目的:对原发性肝细胞癌(HCC)患者的CYP2C19等位基因进行基因分型,探讨CYP2C19基因多态性与原发性HCC的关系。方法:纳入48例原发性HCC患者和88名健康对照者。设计相应引物,以聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法检测CYP2C19m1和CYP2C19m2突变型等位基因,对两组基因多态性进行分析比较。结果:HCC组CYP2C19慢代谢型(m1/m1和m1/m2)发生率为25.0%(12例),与健康对照组的11.4%(10例)相比差异有统计学意义(P<0.05,OR=3116,95%CI:1140～7113)。结论:CYP2C19慢代谢型与原发性HCC之间存在相关性,可能增加人群对HCC的易感性。
Cytochrome P450 （CYP） 2C19 polymorphism is associated with variable ability to metabolize mephenytoin, known as the extensive metabolizer and poor metabolizer. Mutant allele is the molecular biology basis of CYP2C19 gene polymorphism. Aims： To appraise the genotypes of CYP2C19 alleles in patients with primary hepatocellular carcinoma （HCC） and to clarify the relationship between CYP2C19 gene polymorphism and primary HCC. Methods： Forty-eight primary HCC patients and 88 healthy controls were enrolled in this study. Primers were designed and mutants CYP2C19ml and CYP2C19m2 were tested by polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP）. The gene polymorphism of these two groups was analyzed and compared. Results： CYP2C19 poor metabolizers （ml/ml and ml/m2 genotypes） were found in 12 cases （25.0%） of HCC group whereas only in 10 （11.4%） of the healthy controls, the difference was statistically significant （P〈0.05, OR=3116, 95% CI： 1140-7113）. Conclusions： CYP2C19 poor metabolizer has some correlation with primary HCC, and this may increase the susceptibility to HCC,
出处
《胃肠病学》
2008年第1期39-41,共3页
Chinese Journal of Gastroenterology
基金
江苏省南通市科技局社会发展科技计划立项课题(S5018)
